Morgan Stanley increases Gilead Sciences’ target to $127.00

Morgan Stanley increases Gilead Sciences’ target to $127.00

Gilead Sciences is now a recommended buy according to 28 ratings firms that are covering the firm. Although one research analyst has the stock listed as a sell, and four have issued a hold, 20 are calling it a buy a two are giving it a strong buy recommendation, according to a WKRB report. The […]

Gilead Sciences is now a recommended buy according to 28 ratings firms that are covering the firm.

Although one research analyst has the stock listed as a sell, and four have issued a hold, 20 are calling it a buy a two are giving it a strong buy recommendation, according to a WKRB report.

The one-year price objective among brokerages is $127.39. Shares of Gilead Sciences were down 6.28 percent on Monday, reaching $105.33, with a trading volume of 22,739,40 shares.

Gilead Sciences has experienced a 52-week low of $85.95, and its 52-week high was $123.37.

The average price over 50 days is $115.71, and $108.73 over 200 days.

Gilead Sciences issued quarterly earnings results back in late July, reported $3.15 earnings per share, beating previous estimates of $2.83. It had also earned $8.22 billion during the quarter, up 25.8 percent year over year.

In addition, the firm had a quarterly dividend that will pay at the end of September. The dividend is about $0.43 per share.

Gilead Sciences is a research-based biopharmaceutical company that is responsible for developing medicines. It focuses on liver diseases like hepatitis as well as human immunodeficiency virus (HIV).

Like This Post? ... Then Like Our Page :)

Sharing

Facebooktwittergoogle_plusredditpinterestlinkedintumblrmail
Loading...

Leave a Reply

Your email address will not be published. Required fields are marked *